Nanjing Hicin Pharmaceutical Co Ltd (300584) - Total Liabilities
Based on the latest financial reports, Nanjing Hicin Pharmaceutical Co Ltd (300584) has total liabilities worth CN¥415.66 Million CNY (≈ $60.82 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 300584 net assets growth trend to track the company's year-over-year net asset growth rate.
Nanjing Hicin Pharmaceutical Co Ltd - Total Liabilities Trend (2012–2025)
This chart illustrates how Nanjing Hicin Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 300584 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Nanjing Hicin Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Nanjing Hicin Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Attacq
JSE:ATT
|
South Africa | ZAC9.24 Billion |
|
Ranhill Holdings Ltd
KLSE:5272
|
Malaysia | RM2.33 Billion |
|
Jiangsu Transimage Technology Co Ltd
SHE:002866
|
China | CN¥1.86 Billion |
|
Santacruz Silver Mining Ltd.
V:SCZ
|
Canada | CA$237.69 Million |
|
Cowealth Medical China Co.Ltd.
SHG:603122
|
China | CN¥367.76 Million |
|
Zhejiang Starry Pharm Co Ltd
SHG:603520
|
China | CN¥3.69 Billion |
|
Talkspace Inc
NASDAQ:TALK
|
USA | $19.95 Million |
|
PNE AG
XETRA:PNE3
|
Germany | €1.13 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Nanjing Hicin Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 300584 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nanjing Hicin Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nanjing Hicin Pharmaceutical Co Ltd (2012–2025)
The table below shows the annual total liabilities of Nanjing Hicin Pharmaceutical Co Ltd from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥432.26 Million ≈ $63.25 Million |
+1.38% |
| 2024-12-31 | CN¥426.37 Million ≈ $62.39 Million |
+1.19% |
| 2023-12-31 | CN¥421.37 Million ≈ $61.66 Million |
+22.71% |
| 2022-12-31 | CN¥343.38 Million ≈ $50.25 Million |
-2.87% |
| 2021-12-31 | CN¥353.53 Million ≈ $51.73 Million |
+55.37% |
| 2020-12-31 | CN¥227.55 Million ≈ $33.30 Million |
+5.74% |
| 2019-12-31 | CN¥215.19 Million ≈ $31.49 Million |
+0.91% |
| 2018-12-31 | CN¥213.26 Million ≈ $31.21 Million |
+86.07% |
| 2017-12-31 | CN¥114.61 Million ≈ $16.77 Million |
+21.08% |
| 2016-12-31 | CN¥94.66 Million ≈ $13.85 Million |
+8.12% |
| 2015-12-31 | CN¥87.55 Million ≈ $12.81 Million |
-6.50% |
| 2014-12-31 | CN¥93.63 Million ≈ $13.70 Million |
+24.04% |
| 2013-12-31 | CN¥75.49 Million ≈ $11.05 Million |
+30.09% |
| 2012-12-31 | CN¥58.03 Million ≈ $8.49 Million |
-- |
About Nanjing Hicin Pharmaceutical Co Ltd
Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company's products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefuroxime sodium, ceftriaxone hydrochloride, ganciclovir sodium, adenosine monophosphate, and adenosine monophosphate for … Read more